Philips Reaches Settlement in DreamStation Probe
The agreement in principle with the US Department of Justice resolves criminal and civil investigations tied to the recall of millions of sleep apnoea devices.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you trust large companies to fix defective products without government pressure?
Philips reached an agreement in principle with the US Department of Justice to resolve previously disclosed criminal and civil investigations over its DreamStation recall. The company set aside 288 million euros ($322 million) in the third quarter to cover the case, and the settlement remains subject to finalisation of documentation.
Why it matters
The recall of millions of DreamStation sleep apnoea devices followed concerns that users could inhale pieces of noise-cancelling foam, a risk that prompted the government probes. Resolving the matter removes a major legal overhang for the Amsterdam-based company.
Philips booked a 288 million euro provision in the third quarter, cutting quarterly profit to 28 million euros from 187 million euros a year earlier on turnover of 4.4 billion euros. The final settlement terms have not yet been fully documented.
The players
Philips
Philips is a Dutch health technology company headquartered in Amsterdam that makes medical devices including sleep apnoea equipment.
Roy Jakobs
Roy Jakobs is the chief executive of Philips who led the company through its recent restructuring and profit recovery.
US Department of Justice
The US Department of Justice is the federal agency responsible for enforcing US law, including the criminal and civil investigations into the DreamStation recall.
The details
Chief executive Roy Jakobs said the deal was clinched in the last few days and presented the settlement as part of the third-quarter results. The recall was prompted by concerns that users were at risk of inhaling foam pieces and a potential cancer risk.
Timeline
November 3, 2026: Philips announced the agreement in principle with the US Department of Justice.
Third quarter 2026: Philips set aside 288 million euros to settle the case.
First quarter 2027: Payment to settle the case is expected.
Market Landscape
The DreamStation recall of 2021 led to sustained regulatory scrutiny of sleep apnoea device makers, and this settlement closes one of the largest chapters of that episode. It signals how the medical device industry is resolving product-safety liabilities through negotiated agreements rather than prolonged litigation.
Philips DreamStation owners are not directly affected by the settlement terms, which concern the company's liability rather than device replacements. The resolution may influence how device makers approach product-safety disclosures and recall handling going forward.
The takeaway
Resolving major recall investigations through settlement can clear a company's financial outlook, but the underlying safety concerns that prompted the DreamStation recall remain central to device users and regulators.
What happens next
Payment to settle the case is expected in the first quarter of 2027, once the settlement documentation is finalised.
Further reading
Explore more on Healthcare coverage across the industry.
Source note: This article includes information reported by Mail Online.
Live Poll
Do you trust large companies to fix defective products without government pressure?
